How to Buy Insmed Stock
Insmed Inc
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.
Insmed stock last closed at $145.93, up 0.1% from the previous day, and has increased 97.44% in one year. It has overperformed other stocks in the Biotechnology industry by 1.46 percentage points. Insmed stock is currently +141.61% from its 52-week low of $60.40, and -2.11% from its 52-week high of $149.08.
As of Sep 12, 2025, there are 182.14M shares of INSM outstanding. The market cap of INSM is $26.58B. In the past 24 hours, 1.93M INSM shares were traded.
How to Buy Insmed Stock
Wondering how to invest in Insmed stock? Here's how.
- Figure out where to buy Insmed stock: You need to pick a stock brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you choose where to buy Insmed stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Choose your method of payment and add your information.
- Analyze Insmed stock: The Insmed ticker symbol is INSM. Is Insmed stock a good investment? Should you buy shares of INSM? How do INSM's underlying business fundamentals look? Do top analysts think Insmed is a good buy? Why has INSM's stock price moved recently? (Hint: Our stock market analysis website can help you understand if INSM is a good stock to buy).
- Place your INSM buy order: Decide if you will purchase INSM shares at the current market price or use a limit order to purchase INSM shares at a given price.
- Get updates on your investment in INSM: Create a watchlist to key updates about your investment in Insmed stock.
Step 1: Figure out where to buy Insmed stock
You will need a brokerage account to access the NASDAQ market and buy INSM stock.
Our favorite brokerage: eToro
Based on our experience, eToro is the best brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Technology to Real Estate, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the best brokerage, it's time to fill out some personal details so you can buy INSM stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to open a new trading account.
- Send your data by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you have filled out your info on the best stock broker app, your next step is to transfer the money for your investment:
Watch the video below for more details transferring funds into your brokerage account.
Step 4: Analyze Insmed stock
Once you have identified the best place to buy Insmed stock, it's very important to evaluate their stock prior to buying, so you actually comprehend the risk as well as the upside.
Insmed shares at a glance
INSM Due Diligence Checks
WallStreetZen was created to help average investors perform better fundamental analysis.
You can view all of the due diligence checks on INSM's stock page.
Is INSM stock undervalued or overvalued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge INSM's fair value.
Using relative valuations metrics:
- INSM could be overvalued based on its P/B ratio of 268.05x, relative to Biotechnology industry P/B ratio of 4.65x
You can do more valuation analysis on INSM's stock here.
Is INSM a healthy company?
Passed Financial Due Diligence Checks:
- INSM has cash burn of 789249000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the INSM balance sheet.
Failed Financial Due Diligence Checks:
- INSM has $1.20B in cash and short term investments. This is not enough to cover its annual cash burn of $789.25M.
- There are more long-term liabilities than short-term assets on the INSM balance sheet.
- Total INSM debt is higher than 5 years ago, relative to shareholder equity.
- INSM profit margin has gone down from -236.7% to -265.9% in the past year.
- INSM has a relatively high debt to equity ratio of 17.18.
Is it a good time to buy Insmed stock, according to analysts?
Out of 16 Equities analysts who give recommendations on INSM, the consensus analyst rating on INSM is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Latest INSM Analyst Upgrades/Downgrades
Stephen Willey, a bottom 9% analyst from Stifel Nicolaus maintains INSM with a strong buy rating and raises their INSM price target from $121.00 to $145.00, on Aug 14, 2025.
Andrew S. Fein, a top 34% analyst from HC Wainwright & Co. maintains INSM with a buy rating and raises their INSM price target from $120.00 to $240.00, on Aug 13, 2025.
Trung Huynh, a top 11% analyst from UBS maintains INSM with a strong buy rating and raises their INSM price target from $133.00 to $140.00, on Aug 13, 2025.
UBS's Trung Huynh raised their price target on Insmed (NASDAQ: INSM) by 5.3% from $133 to $140 on 2025/08/13. The analyst maintained their Strong Buy rating on the stock.
Hiking their price target on Insmed, Huynh said that "the approval of Brinsupri comes with an 'in-line' label, so investors will now focus on launch execution."
Earnings Report
For Q2 2025, Insmed reported:
- Loss per share of $1.70, which missed the Zacks Consensus Estimate of $1.3 but beat, by 12.4%, Q2 2024’s $1.94.
- Revenue of $107.42M, which beat the Zacks Consensus Estimate by 3.87% and, by 18.9%, Q2 2024’s $90.34M.
For FY 2025, management guided:
- Revenue of $405M to $425M.
Chairman & CEO Will Lewis commented: "Q2 2025 heralded another important milestone for patients and Insmed, with the Phase 2b PAH study of TPIP yielding topline results that surpassed our expectations.
"Insmed is now 'three for three' in terms of positive clinical trial results for our late-stage assets, and we have a line-up of additional anticipated milestones with the potential to expand our impact on patients expected over the next twelve months.
“Our teams continue to demonstrate executional excellence as we await the widely anticipated FDA approval and launch of brensocatib in bronchiectasis, advance our TPIP program in both PH-ILD and PAH, prepare for topline data from our Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps by the end of the year, and progress toward the read-out of our Phase 3 ENCORE study of ARIKAYCE in 1H 2026.
“Importantly, each of these events represents an opportunity to fulfill Insmed's mission to transform the lives of patients with serious diseases."
Leonid Timashev, a top 30% analyst from RBC Capital maintains INSM with a buy rating and raises their INSM price target from $120.00 to $138.00, on Aug 13, 2025.
Andrea Tan, a bottom 2% analyst from Goldman Sachs maintains INSM with a strong buy rating and raises their INSM price target from $114.00 to $142.00, on Aug 13, 2025.
You can dive deeper into what analysts are saying on the Insmed stock forecast page.
INSM Technical Indicators
INSM Growth Metrics
Last year, INSM revenue was $381.03M. During the past 5 year, INSM's revenue has gone up by 20.27% per year. This was slower than the Biotechnology industry average of 66.52%.
Dig into INSM's earnings and revenue performance here.
Who is buying/selling INSM?
In the last year, insiders at INSM have sold more shares than they have bought.
Martina Md Flammer, Chief Medical Officer of INSM, was the latest INSM insider to buy. They bought $465,530.40 worth of INSM shares on Sep 2, 2025.
Research more about who owns INSM stock here.
Does INSM stock generate passive income?
No, Insmed doesn't provide an income stream by paying out dividends.
What do other investors have to say about INSM?
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Place your INSM buy order
There are two main order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly the easiest way to buy. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a particular dollar amount, place a limit order.
Hit the Open Trade button and your broker will place your order.
If you require more help with buying stocks on eToro, click the helpful video below:
Step 6: Get updates on your investment in INSM
Now that you own some INSM shares, you'll want to stay up-to-date on your shares.
Add INSM to a watchlist to keep tabs on your INSM stock.
INSM Feed
How to Buy Stock in Insmed
To reiterate, here are the 6 steps you need to take to buy Insmed stock right now:
- Figure out where to buy Insmed stock
- Sign up for your brokerage account
- Deposit funds into your brokerage account
- Analyze Insmed stock
- Place your INSM buy order
- Get updates on your investment in INSM
If you require a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to get notifications regarding your investment in Insmed, create your watchlist below.
Related Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.